Returning to PARP inhibition: Rechallenge with Bevacizumab in Ovarian Cancer.
Where this comes from
- Record sourced from PubMed, PMID 42024147.
- Also identified by DOI 10.1158/1078-0432.CCR-26-0534.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The KGOG 3056/NIRVANA-R trial demonstrated that niraparib rechallenge combined with bevacizumab may potentially be a promising maintenance strategy in patients with platinum-sensitive recurrent ovarian cancer (PSROC) previously treated with PARPi. With a 68% 6-month progression-free survival (PFS) rate, this combination may synergistically be able to overcome acquired PARPi resistance, particularly in patients with favorable platinum sensitivity.